ストックスクリーナーアプリを入手
0.9806
0.54%
-0.0092
前日終値:
$0.9898
開ける：
$1
24時間の取引高:
172.89K
Relative Volume:
0.19
時価総額：
$102.52M
収益：
-
当期純損益:
$-93.61M
株価収益率:
-0.4647
EPS:
-2.11
ネットキャッシュフロー:
$-71.16M
1週間 パフォーマンス:
-0.08%
1か月 パフォーマンス:
+7.23%
6か月 パフォーマンス:
-9.68%
1年 パフォーマンス:
-23.09%
1日の値動き範囲:
$0.97
$1.02
1週間の範囲:
$0.95
$1.05
52週間の値動き範囲:
$0.8319
$2.11
Immunic Inc Stock (IMUX) Company Profile
IMUX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.98 | 102.52M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.05 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.88 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
534.44 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.00 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.78 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | 開始されました | William Blair | Outperform |
| 2024-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-27 | 開始されました | B. Riley Securities | Buy |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-04-15 | 開始されました | Aegis Capital | Buy |
| 2021-03-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-08-07 | 再開されました | ROTH Capital | Buy |
| 2020-07-20 | 開始されました | BMO Capital Markets | Outperform |
| 2020-06-05 | 開始されました | Wedbush | Outperform |
| 2020-05-11 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-25 | 開始されました | ROTH Capital | Buy |
| 2019-07-11 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Immunic Inc (IMUX) 最新ニュース
Immunic (IMUX) Projected to Post Earnings on Wednesday - Defense World
Immunic CMO on Celiac Disease Awareness Month, potential of IMU-856 - Proactive financial news
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial - Proactive financial news
36,811 Shares in Immunic, Inc. (NASDAQ:IMUX) Acquired by Invesco Ltd. - Defense World
Immunic (IMUX) Stock Price, News & Analysis - MarketBeat
Where Do Analysts See Immunic Inc (NASDAQ: IMUX) Heading? - Stocksregister
Renaissance Technologies LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital - Defense World
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic to Participate in Scientific and Industry Conferences in May | IMUX Stock News - GuruFocus
Immunic to Participate in Scientific and Industry Conferences in May - The Malaysian Reserve
Immunic presses ahead with MS drug despite Phase II endpoint miss - Yahoo
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Pr - GuruFocus
What is Immunic Inc (IMUX) Stock Return on Shareholders’ Capital? - Sete News
Daily Progress: Immunic Inc (IMUX) Drop -22.65, Closing at 0.99 - DWinneX
MS drug shows promise in progressive cases, despite missed trial goal - The Pharma Letter
Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News - GuruFocus
Immunic Inc (IMUX) rating initates by William Blair - knoxdaily.com
How will Immunic Inc’s (IMUX) earnings compare to estimates this quarter? - uspostnews.com
Small cap wrap: ReconAfrica, Power Metallic, Immunic, Replenish Nutrients... - Proactive Investors
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
Immunic Announces Vidofludimus Calcium Reduced Risk of Disabilit - GuruFocus
Immunic reports reduced disability worsening in progressive multiple sclerosis trial - Proactive financial news
Immunic (IMUX) Reports Promising Phase 2 Results for Vidofludimu - GuruFocus
Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug - GuruFocus
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Price Target | IMUX Stock News - GuruFocus
Immunic Announces Vidofludimus Calcium Reduced Risk Of Disability Worsening By 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial - marketscreener.com
Immunic reports progress in multiple sclerosis trial - Investing.com Australia
Immunic stock drops after mid-stage trial data (IMUX:NASDAQ) - Seeking Alpha
Immunic Inc Inc. (IMUX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial | IMUX Stock News - GuruFocus
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - Yahoo Finance
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha
Immunic Inc (IMUX) Offers An Excellent Investment Opportunity At Current Levels - Stocksregister
One Immunic Insider Raised Their Stake In The Previous Year - Yahoo Finance
Trading Day Review: Immunic Inc (IMUX) Gains Momentum, Closing at 1.14 - DWinneX
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $13.20 - Defense World
IMUX: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Immunic Inc (IMUX) stock on the rise: An overview - uspostnews.com
Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Optimistic View of Immunic FY2025 Earnings - Defense World
HC Wainwright Estimates Immunic’s Q1 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st
Immunic Stock Price, Quotes and Forecasts | NASDAQ:IMUX - Benzinga
Immunic, Inc. Announces Closing of $5.1 Million Registered Direc - GuruFocus
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - The Malaysian Reserve
Immunic Closes of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - citybiz
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Eastern Progress
Immunic Raises $5.1 Million From Direct Stock Offering - marketscreener.com
Immunic Inc (IMUX) 財務データ
収益
当期純利益
現金流量
EPS
0.40%
0.05%
大文字化:
|
ボリューム (24 時間):